Is plateau normal?
Yes, it's a feature of weight loss biology.
Can I push past plateau?
Sometimes, through dose escalation, product switch, tightened lifestyle, or resistance training.
When does plateau typically happen?
Week 28-40 on semaglutide at therapeutic doses.
Should I increase my dose?
Yes if not at maximum; if at 2 mg, consider product change.
How long before changing strategy?
8-12 weeks of true plateau at maximum tolerated dose.
Will I gain back weight?
Continued therapy typically maintains loss.
Is it okay to stop at the weight I've lost?
Often the right answer; maintenance is legitimate.
Could it be the medication wearing off?
Tolerance is uncommon; plateau is biological adaptation.
Should I switch products?
Reasonable consideration at max Ozempic; Wegovy 2.4 mg or tirzepatide common options.
Related guides
- Why Am I Not Losing Weight on Mounjaro? Plateau Patterns and Real Causes
- Does Ozempic Make You Cold? Thermoregulation After Rapid Weight Loss
- Why Am I Not Losing Weight on Zepbound? Plateau Realities and Course Correction
- How Often Should I Poop on Ozempic? Bowel Patterns Explained
- Ozempic and Loose Skin: A Weight-Loss Phenomenon, Not an Ozempic Phenomenon
- Why Am I Not Losing Weight on Ozempic? The Six Causes Worth Investigating
Sources
- Wilding JPH et al., STEP 1, NEJM March 2021
- Rubino D et al., STEP 4, JAMA April 2021
- Lincoff AM et al., SELECT, NEJM November 2023
- Jastreboff AM et al., SURMOUNT-1, NEJM July 2022
- Aronne LJ et al., SURMOUNT-4, JAMA January 2024
- Ozempic FDA prescribing information
- Wegovy FDA prescribing information
- Tasali E et al., JAMA Internal Medicine March 2022
- Endocrine Society Clinical Practice Guideline on Obesity, 2023
- ACSM resistance training guidelines
- National Sleep Foundation duration guidance
Footer disclaimers
Platform Disclaimer. FormBlends connects patients with licensed clinicians for GLP-1 therapy. This article is educational. Individual situations require clinical assessment by your prescriber.
Get medications from a trusted source
FormBlends sources through 503A compounding pharmacies with third-party purity testing on every batch.
Start Free Assessment →Compounded Medication Notice. Compounded semaglutide is prepared by 503A pharmacy partners for individual patients with documented clinical justification. Not FDA-approved. STEP trial data applies to brand Wegovy and Ozempic.
Results Disclaimer. Individual outcomes vary. STEP 1 mean of 14.9% includes high responders and modest responders. Plateau is expected; maintenance is a legitimate outcome.
Trademark Notice. Ozempic, Wegovy are trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are trademarks of Eli Lilly. FormBlends is independent.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →